Compare Novavax Inc (NVAX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Vanguard Dividend Appreciation Index Fund ETF trades at $236.95. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VIG | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $239.13 |
52-Week Low | $6.22 | $204.09 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
VIG trades at $236.97, down 0.27% today, with a bullish technical signal from moving averages and oversold RSI_6 at 28.87. Support lies at $235, resistance at $237. The ETF focuses on dividend growth from high-quality U.S. large-caps, with a dividend of $1.00 scheduled for June 2026. Recent news highlights its role in long-term wealth building and diversification away from tech concentration.
Outlook remains positive for income-focused investors seeking stability, though reliance on dividend growth stocks exposes VIG to interest rate sensitivity and economic slowdowns. Its low expense ratio and quality screen support compounding, but yield competition from bonds or higher-dividend ETFs like VYM poses a relative value risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
